The Ministry of Science and ICT of South Korea convened the 44th Comprehensive Policy Council on Biotechnology on March 18, unveiling a joint national R&D strategy for the future brain industry. The initiative responds to rapid global advances in brain-computer interface (BCI) technology, such as Elon Musk’s Neuralink and China’s approval of invasive BCI medical devices. The government aims to position South Korea as a ‘first mover’ by leveraging domestic research ecosystems in neuroscience, artificial intelligence, healthcare, and advanced manufacturing. This strategy is part of the broader K-Moonshot program, targeting transformative innovation in brain-related industries.
The policy impacts patients with spinal cord injuries, visual impairments, and other neurological conditions, as well as researchers, startups, and major companies in the BCI sector. Seven mission-driven projects will begin next year, focusing on implantable chips to overcome physical limitations, treat brain diseases, and restore sensory functions. Non-invasive BCI technologies will be commercialized early for use in wearable devices across healthcare, entertainment, and defense. Dedicated project managers will form multidisciplinary teams to integrate and support key technologies from research to market.
Implementation starts in 2025, with regulatory collaboration between the Ministry of Food and Drug Safety and industry alliances to accelerate clinical trials and commercialization. The government will expand R&D support for core technologies such as brain implant electrode materials, neural network-specific semiconductors, and neural signal decoding. Regional brain industry clusters will be developed around leading institutions like the Korea Brain Research Institute in Daegu and the Korea Research Institute of Bioscience and Biotechnology in Daejeon. Long-term goals include building a digital twin of the human brain and replacing animal testing with organoids and digital models.
Frequently asked questions include: What are the main objectives of the strategy? The policy aims to advance BCI technology for medical, industrial, and societal applications, and to establish South Korea as a global leader. Who will benefit from these initiatives? Patients, researchers, startups, and companies in the brain industry will gain from improved clinical support, regulatory frameworks, and commercialization opportunities. The government will also develop guidelines for clinical research and foster regional clusters to support innovation.
South Korea’s national R&D strategy for the brain-computer interface industry demonstrates a forward-thinking policy response to global advances in neurotechnology. By prioritizing mission-driven projects, regulatory collaboration, and regional cluster development, the government aims to accelerate both clinical and commercial progress. The integration of AI, advanced materials, and digital brain modeling is expected to foster innovation and competitiveness. This approach may enable South Korea to establish itself as a leader in the future brain industry, benefiting patients, researchers, and technology companies.